JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
JP Morgan has maintained its Neutral rating for Ionis Pharmaceuticals (NASDAQ:IONS) but raised its price target from $52.00 to $55.00. Ionis Pharmaceuticals, a leader in antisense technology for drug development, has seen its shares increase by 0.62% in the last 24 hours to $51.71. The new price target represents a 6.36% potential upside. Ionis has successfully brought several drugs to market, including treatments for spinal muscular atrophy and ALS, through partnerships and its subsidiaries.
February 01, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan maintains Neutral rating on Ionis Pharmaceuticals but raises price target from $52 to $55, indicating a potential upside of 6.36%.
The increase in the price target by JP Morgan suggests a positive outlook on Ionis Pharmaceuticals' stock, potentially leading to increased investor confidence and a short-term rise in stock price. The company's successful track record in bringing drugs to market, including recent launches, supports this optimism. However, the Neutral rating indicates that there may be factors limiting the stock's upside potential in the very short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100